Overcoming the compensatory increase in NRF2 induced by NPL4 inhibition enhances disulfiram/copper-induced oxidative stress and ferroptosis in renal cell carcinoma

• Published in: European journal of pharmacology 2023-12, Vol.960, p.176110-176110, Article 176110
• Main Authors: Ni, Xinmiao, Ye, Chenglin, Yu, Xi, Zhang, Ye, Hou, Yanguang, Zheng, Qingyuan, Chen, Zhiyuan, Wang, Lei, Weng, Xiaodong, Yang, Chuan, Liu, Xiuheng
• Format: Article
• Language: English
• Subjects: Animals; Carcinoma, Renal Cell - drug therapy; Copper - pharmacology; Disulfiram; Disulfiram - pharmacology; Ferroptosis; Kidney Neoplasms - drug therapy; Mice; NF-E2-Related Factor 2 - metabolism; NPL4; NRF2; Oxidative Stress; Renal cell carcinoma; Sorafenib - pharmacology
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2023.176110

Renal cell carcinoma (RCC) is the most common type of kidney cancer, and it appears to be highly susceptible to ferroptosis. Disulfiram, an alcoholism drug, has been shown to have anticancer properties in various studies, including those on RCC. However, the mechanisms underlying the disulfiram/copper-induced anticancer effects in RCC remain unclear. In this study, we investigated the impact of disulfiram/copper on RCC treatment using both RCC cells and mouse subcutaneous tumor models. Our findings demonstrate that disulfiram/copper treatment reduced the viability of RCC cells, inhibited their invasion and migration, and disrupted mitochondrial homeostasis, ultimately leading to oxidative stress and ferroptosis. Mechanistically, disulfiram/copper treatment prolonged the half-life of NRF2 and reduced its degradation, but had no effect on transcription, indicating that the disulfiram/copper-induced increase in NRF2 was not related to transcription. Furthermore, we observed that disulfiram/copper treatment reduced the expression of NPL4, a ubiquitin protein-proteasome system involved in NFR2 degradation, while overexpression of NPL4 reversed NRF2 levels and enhanced disulfiram/copper-induced oxidative stress and ferroptosis. These results suggest that overcoming the compensatory increase in NRF2 induced by NPL4 inhibition enhances disulfiram/copper-induced oxidative stress and ferroptosis in RCC. In addition, our in vivo experiments revealed that disulfiram/copper synergized with sorafenib to inhibit the growth of RCC cells and induce ferroptosis. In conclusion, our study sheds light on a possible mechanism for disulfiram/copper treatment in RCC and provides a potential synergistic strategy to overcome sorafenib resistance.